Regeneron Pharmaceuticals Inc

$ 367.64
Updated 13/07/2018
Change % 0.00% Stock price unchanged
Change 0.00 Stock price unchanged
Volume 205,001
High $ 370.14
Low $ 364.74
Open $ 366.30
Prev close $ 366.43
# of shares 105.95M
Market cap 38,951M USD

Market closed
Regeneron Pharmaceuticals Inc
Market is closed, opens at 14:30
Price development Latest 1 week 1 month 3 months 6 months 1 year
  367.64 -0.5% Stock price decreasing 16.6% Stock price increasing 14.3% Stock price increasing 0.2% Stock price increasing -27.2% Stock price decreasing
Powered by TradingView

News about Regeneron Pharmaceuticals Inc

  • English
  • Regulatory news

Company profile

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
15 July 2018 21:50:21
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180712.1 - EUROWEB2 - 2018-07-15 22:50:21 - 2018-07-15 21:50:21 - 1000 - Website: OKAY